T-TAs® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion
Sanz, Cristina (Banc de Sang I Teixits)
Escolar, Ginès (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Diaz-Ricart, Maribel (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Samanbar, Sahar (Universitat de Barcelona)
Piñeyroa, Juan A. (Hospital Clínic i Provincial de Barcelona)
Moreno-Castaño, Ana B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pino, Marc (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Torramadé-Moix, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona)

Fecha:	2024
Resumen:	background - Current laboratory tests fail to evaluate the hemostatic function of platelets in patients with thrombocytopenia. We investigated the use of the Total Thrombus-Formation Analysis System (T-TAS® 01 [Fujimori Kogyo Co, Tokyo, Japan]) to evaluate hemostasis under conditions of experimental thrombocytopenia, and in patients before and after platelet transfusion. materials and methods - Specific T-TAS 01 chips, for thrombocytopenic conditions, were used. The area under the curve (AUC) and occlusion time (OT, min) were measured in: (i) experimentally induced thrombocytopenia (183±15 to 6. 3±1. 2×10 platelets/µL) in blood samples from healthy donors (No. =13), and (ii) blood from oncohematological thrombocytopenic patients (No. =48), before and after platelet transfusion. The influences of hematocrit and number of transfusions were analyzed in these patients. results - Progressive reductions of AUC and prolongations of OT related significantly to decreasing platelet counts (p<0. 05 for all) in experimental thrombocytopenia. In samples from thrombocytopenic patients, platelet counts, AUC and OT were, respectively, 10. 8±0. 6×10/µL, 175. 2±59, and 27. 2±1 min before transfusion; and 22±1. 5×10/µL, 400. 8±83 and 22. 9±1. 5 min after platelet transfusion (p<0. 01 for all). A hematocrit below 25% or exposure to ten or more previous platelet transfusions had a negative impact on the T-TAS 01 performance in patients. In vitro correction of the hematocrit improved the hemostatic response in thrombocytopenic patients. discussion - T-TAS 01 measurements were sensitive to low platelet counts in the experimental setting. The technology was sensitive to evaluate the hemostatic capacity of platelet transfusions. Exposure to multiple medications, repeated platelet transfusions and lower hematocrits may interfere with the hemostatic performance in oncohematological patients with thrombocytopenia.
Ayudas:	Instituto de Salud Carlos III PI19/00888 "la Caixa" Foundation 202026-10 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-675
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Thrombocytopenia ; Total thrombus-formation analysis system (T-TAS) ; Platelet transfusion ; Bleeding
Publicado en:	Blood Transfusion, Vol. 22 Núm. 2 (march 2024) , p. 166-175, ISSN 2385-2070

DOI: 10.2450/BloodTransfus.550
PMID: 38063791

10 p, 1.9 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Instituto de Investigación contra la Leucemia Josep Carreras
Artículos > Artículos de investigación
Artículos > Artículos publicados